603716 Thalys Medical Technology Group Corporation.
- 6.85
- +0.02+0.29%
Thalys Medical Technology Group Corporation. News
Saili Healthcare (603716.SH): Net profit of 3.156,800 yuan in the first quarter
On April 27, Ge Longhui Medical (603716.SH) released its report for the first quarter of 2024, achieving operating income of 485 million yuan, an increase of 9.24% over the previous year; net profit attributable to shareholders of listed companies was 3.156,800 yuan, net profit attributable to shareholders of listed companies was 9097 million yuan after deducting non-recurring profit and loss, with basic earnings of 0.02 yuan per share.
Saili Healthcare (603716.SH) announced first-quarter results, net profit of 3.156,800 yuan
According to the Zhitong Finance App, Saili Healthcare (603716.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 485 million yuan, an increase of 9.24% over the previous year; net profit attributable to shareholders of listed companies was 3.156,800 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 9097 million yuan; and basic earnings per share were 0.02 yuan.
China Securities Peng Yuan: Concerned that Saili Healthcare has received a notice from the China Securities Regulatory Commission to file a case
CSRC Peng Yuan is concerned that due to the suspected illegal disclosure of information, the China Securities Regulatory Commission decided to file a case against the company in accordance with relevant laws and regulations. CSIC Peng Yuan will continue to monitor the subsequent progress of the above matters, and will pay close attention to the possible impact of changes in the company's external operating environment, operating conditions and financial conditions on the company's entities' credit ratings, rating prospects, and “Saili Convertible Bonds” credit ratings.
Saili Healthcare (603716.SH): Shares were not repurchased in March
Gelonghui, April 1, 丨 Saili Healthcare (603716.SH) announced that in March 2024, the company did not buy back shares through centralized bidding transactions through the Shanghai Stock Exchange trading system. As of March 31, 2024, the company has repurchased 2,070,000 shares through centralized bidding transactions through the Shanghai Stock Exchange trading system. The repurchased shares account for 1.0282% of the company's total share capital. The highest transaction price of the repurchased shares is 6.59 yuan/share, the lowest transaction price is 5.37 yuan/share, and the total amount paid is RMB 12,976,843 (excluding transaction)
Express News | Saili Healthcare: Received a notice of filing a case from the China Securities Regulatory Commission due to the company's suspected illegal disclosure of information
A-share changes丨The AI medical concept is repeatedly active, and the Berry gene is linked to 3 links
Gelonghui, March 20 | Berry Genomics and Celi Medical are on the 3rd board. Runda Healthcare hit a rise or fall, while Wanda Information, Hongbo Pharmaceuticals, and Sichuang Medical Benefits followed suit. According to the news, Novo Nordisk Foundation announced a few days ago that it has reached an agreement with Nvidia to build a superAI computer called “GEFION” for the Nordic country Denmark to lead the country into the AI field. Furthermore, at its annual health event “The Check Up,” Google announced a series of new initiatives to apply artificial intelligence (AI) models to the healthcare industry.
Express News | Saili Healthcare: The company advocates value investment and will focus on the development of the main business. The company kindly invites investors to pay attention to secondary market transaction risks.
The AI medical concept continues to be strong, Saili Medical's 2-in-1
Gelonghui, March 19 | Celi Medical and Berry Genes are on the same page. Aladdin and Hongbo Pharmaceuticals rose more than 7%, while Yahong Pharmaceutical and Anbiping followed suit. According to the news, Nvidia launched 25 new microservices (NIM) based on medical scenarios at the GTC conference to help global healthcare companies improve efficiency based on generative AI.
A-share SPD concept stocks fluctuated and rose, and Hefu China went up and down in a straight line
Gelonghui, March 18 | Hefu China went up and down in a straight line. Saili Medical was previously closed, and Runda Healthcare, Guoxin Health, Kaikai Industrial, and Zhejiang Zhenyuan followed suit.
The A-share DRG concept was active at the beginning of the market, and Seli Healthcare rose or stopped
Gelonghui, March 18 | Selly Healthcare closed, and Jiahe Meikang, Weining Health, and Venture Huikang followed suit.
Saili Healthcare (603716.SH): cumulative repurchase of 1.0282% of the company's shares
Gelonghui, March 4, 丨 Saili Healthcare (603716.SH) announced that as of February 29, 2024, the company had repurchased 2,070,000 shares of the company's shares through centralized bidding transactions. The repurchased shares accounted for 1.0282% of the company's total share capital. The highest transaction price for the repurchase was 6.59 yuan/share, the minimum transaction price was 5.37 yuan/share, and the total amount paid was RMB 12,976,843 (excluding transaction fees).
Saili Healthcare (603716.SH): Cumulative repurchase of 1.0282% of shares as of February 8
Gelonghui, Feb. 8, 丨 Saili Healthcare (603716.SH) announced that as of February 8, 2024, the company had repurchased 2.07 million shares of the company through centralized bidding transactions. The repurchased shares accounted for 1.0282% of the company's total share capital, an increase of 0.2633% compared with the previous disclosure. The highest transaction price for the newly purchased shares was 5.79 yuan/share, and the minimum transaction price was 5.37 yuan/share. The total amount paid was RMB 129.768 million (excluding transaction fees).
Saili Healthcare (603716.SH): 1.54 million shares repurchased for the first time
On February 6, 2024, Gelonghui Healthcare (603716.SH) announced that on February 6, 2024, the company repurchased 1.54 million shares for the first time through the Shanghai Stock Exchange trading system, accounting for 0.7649% of the company's total share capital. The highest price of the repurchase transaction was 6.59 yuan/share, the lowest price was 6.42 yuan/share, and the total capital paid was RMB 9,930,453 (excluding transaction fees).
Saili Healthcare (603716.SH): Plans to spend 10 million yuan to 20 million yuan to buy back shares
On February 5, Gelonghui Medical (603716.SH) announced that the company plans to repurchase the company's shares through centralized bidding transactions; the total repurchase capital shall not be less than RMB 10 million (inclusive) and not more than RMB 20 million, and the repurchase price shall not exceed RMB 12.16 per share (inclusive).
Saili Healthcare (603716.SH): Pre-loss of 115 million yuan to 150 million yuan in 2023
Gelonghui, January 30, 丨 Saili Healthcare (603716.SH) announced the 2023 annual performance pre-loss announcement. It is estimated that net profit attributable to shareholders of listed companies will be -115 million yuan to -150 million yuan in 2023; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss in 2023 is -110 million yuan to -145 million yuan.
Changes in the pharmaceutical business sector pull up, and Celi Healthcare rises and stops
Gelonghui, December 20 | The A-share pharmaceutical business sector has been driven up by fluctuations, Celi Healthcare has risen and stopped, and Kaikai Industrial has risen by more than 4%. Kaikai Industrial, ordinary people, Hefu China, and Chinese Health have followed suit.
Celi Healthcare (603716.SH): The SPD projects of Bishan Second People's Hospital and Bishan Maternal and Child Health Hospital have been launched
Gelonghui November 23|Celi Healthcare (603716.SH) said at the performance briefing that in February 2022, the company signed the Chongqing Bishan Regional SPD construction project with the Chongqing Bishan District People's Government, which mainly includes the construction of projects such as Saili Healthcare's regional lean hospital management platform, regional testing center, harmless treatment of in-hospital medical waste, equipment management cloud service platform, and Internet hospital. Up to now, the SPD projects of Bishan Second People's Hospital and Bishan Maternal and Child Health Hospital have been launched, the key departments of the Bishan People's Hospital SPD project have been launched, and the Bishan Traditional Chinese Medicine Hospital SPD project is under active construction, Chongqing
Seri Healthcare (603716.SH): Net loss of 5.345,200 yuan in the third quarter
Glonghui, Oct. 26, 丨 Saili Healthcare (603716.SH) announced its report for the third quarter of 2023. Revenue for the reporting period was 519 million yuan, down 15.34% from the previous year; net profit attributable to shareholders of listed companies - 5.345,500 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 5155,800 yuan; basic earnings per share - 0.03 yuan/share.
Seri Medical (603716.SH): The preparation of the toxicology batch pilot sample has now been completed
Glonghui, Oct. 20 | Saili Medical (603716.SH) said on the investor interactive platform that it has now completed the preparation of the toxicology batch pilot test samples. If everything progresses smoothly, it is expected that the IND clinical approval application will be submitted before the end of the year.
Seri Healthcare (603716.SH): Efforts are being made to create a model for regional SPD projects with multiple business models and high-quality projects represented by Bishan, Chongqing, etc.
Glonghui, Oct. 10, 丨 Saili Medical (603716.SH) said at the semi-annual performance briefing that the company is based on the unique “SPD+CDSS+DRGS/DIP” solution, and according to the “broad market+regionalized model” raft strategy, further explores the superposition of multiple business models based on regionalized SPD projects (SPD+IVD+ICL+RMLC+ medical waste treatment+medical equipment maintenance). Currently, the company has used the southwest market as a pilot project base for implementing the above strategies, and is focusing on building regionalization represented by Bishan, Chongqing, etc. The SPD project overlaps with multiple business models
Analysis
Price Target
No Data
